Science Driven, Patient Centric Therapies
ALIGOS Therapeutics (aligos.com) scores 77 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 53rd percentile of 9623 Healthcare brands.
ALIGOS Therapeutics is a biotechnology company headquartered in South San Francisco that discovers and develops targeted antiviral and liver disease therapeutics. The company focuses on chronic hepatitis B (CHB), COVID-19, and Nonalcoholic Steatohepatitis (NASH), leveraging expertise in medicinal chemistry and biology. Its mission is to create best-in-class treatments that improve outcomes for patients with liver and viral diseases, addressing unmet medical needs where current therapeutic options are limited.
| Brand Name | ALIGOS Therapeutics |
|---|---|
| Domain | aligos.com |
| Industry | Healthcare |
| Headquarters | South San Francisco |
| Main Competitors | Arbutus Biopharma (80/100), Assembly Biosciences (76/100), Vir Biotechnology (77/100), Enanta Pharmaceuticals, Antios Therapeutics, Gilead Sciences (81/100), Madrigal Pharmaceuticals (83/100), Intercept Pharmaceuticals (71/100) |
Moz Domain Authority 34/100 vs category average 41 / leader 97 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #1,840,787 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "We discover targeted antiviral therapies for chronic hepatitis B (CHB), COVID-19, and optimized therapeutics for Nonalcoholic Steatohepatitis (NASH)." (Meta description: 18 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on Facebook, Instagram, LinkedIn, X (Twitter), YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is ALIGOS Therapeutics?", Claude could identify the brand as of September 2026. Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule and other therapies for chronic liver and viral diseases, particularly hepatitis B and hepatitis D, as well as NASH/MASH. Best known for Developing antiviral and liver disease drug candidates targeting chronic hepatitis B and hepatitis D functional cure approaches.
When asked "Best brands similar to ALIGOS Therapeutics?", Claude would recommend ALIGOS Therapeutics as of September 2026. It's a recognized player in the hepatitis B/D and liver disease drug development space, so it would come up in discussions of biotech companies working on viral hepatitis cures.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
ALIGOS Therapeutics's main competitors in Healthcare: Arbutus Biopharma (80/100), Assembly Biosciences (76/100), Vir Biotechnology (77/100), Gilead Sciences (81/100), Madrigal Pharmaceuticals (83/100).
Sources: Brand Analyzer scan
ALIGOS Therapeutics is a biotechnology company based in South San Francisco that discovers and develops targeted antiviral and liver disease therapies. It focuses on chronic hepatitis B, COVID-19, and Nonalcoholic Steatohepatitis (NASH), aiming to create best-in-class treatments for patients with unmet medical needs in liver and viral diseases.
Sources: ALIGOS Therapeutics official site
ALIGOS Therapeutics has limited AI-search visibility, scoring 30/100 on Brand Analyzer's AI visibility composite (visibility 19, trust 33, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: ALIGOS Therapeutics official site
ALIGOS Therapeutics is headquartered in South San Francisco. ALIGOS Therapeutics operates in the Healthcare category.
Sources: Wikidata
ALIGOS Therapeutics discovers and develops targeted antiviral therapies for chronic hepatitis B and COVID-19, as well as optimized therapeutics for Nonalcoholic Steatohepatitis (NASH). The company applies expertise in medicinal chemistry and biology to build a differentiated pipeline of treatments intended to improve outcomes for patients with liver and viral diseases.
Sources: ALIGOS Therapeutics official site
ALIGOS Therapeutics scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: ALIGOS Therapeutics official site
ALIGOS Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: ALIGOS Therapeutics official site
ALIGOS Therapeutics offers a pipeline of investigational therapeutics rather than commercial products, including targeted antiviral candidates for chronic hepatitis B and COVID-19, and optimized therapeutic candidates for Nonalcoholic Steatohepatitis (NASH). These are developed through the company's expertise in medicinal chemistry and biology as part of ongoing drug discovery and development programs.
Sources: ALIGOS Therapeutics official site
ALIGOS Therapeutics' work is intended for patients with chronic hepatitis B, COVID-19, and NASH, as well as healthcare providers, researchers, and pharmaceutical partners interested in antiviral and liver disease treatments.
Sources: ALIGOS Therapeutics official site
ALIGOS Therapeutics is known for its research and development pipeline targeting chronic hepatitis B, COVID-19, and NASH, using specialized medicinal chemistry and biology expertise to pursue best-in-class antiviral and liver disease treatments.
Sources: ALIGOS Therapeutics official site
ALIGOS Therapeutics scores 30/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
ALIGOS Therapeutics has a weak AI-visibility profile at 30/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is visibility (19/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #1,840,787 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 34/100 and thin schema.org structured data. In a live check, Claude could already identify ALIGOS Therapeutics from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to ALIGOS Therapeutics: Alife (77/100), Alegeus (77/100), Amazing Marvin (77/100), Ambitious about Autism (77/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.